Amphastar Has First US Glucagon Rival
FDA Approves First Generic Version Of Eli Lilly’s Glucagon Emergency Kit
Amphastar has secured the first US approval for a generic version of Eli Lilly’s glucagon emergency kit.
You may also be interested in...
Amphastar delivers back-to-back strong quarters as the company continues to see a rise in sales of its key products including Primatene Mist (epinephrine), glucagon and other epinephrine products. The company continues to build its pipeline and diversify its portfolio.
Sales of Primatene Mist and other higher-margin products drive Amphastar's ifrst-quarter r5esults. The company continues to target a combined market worth around $10.5bn with seven generics in development.
Amphastar has delivered a strong quarter due to an increased in sales of higher-margin products. The company continues to target a combined market worth around $10.5bn with seven generics in development.